Survival post malignant pericardial effusion

被引:5
作者
Nguyen, Olivier [1 ]
Ouellette, Denise [2 ]
机构
[1] Univ Montreal, Fac Surg, Montreal, PQ, Canada
[2] Univ Montreal, Thorac Surgeon Maisonneuve Rosemont Hosp, Montreal, PQ, Canada
关键词
pericardial effusion; malignant disease; subxiphoid window;
D O I
10.4081/cp.2011.e38
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The study reviews the survival of patients with malignant pericardial effusion treated with a subxiphoid pericardial window. The medical records of 60 consecutive patients diagnosed with a malignant pericardial effusion and treated with a subxiphoid pericardial window between 1994 and 2008 were reviewed. 72% had lung cancer. Overall 30-day mortality was 31%. Survival rates at 3 months, 6 months, 1 year, and 2 years were 45%, 28%, 17%, and 9%, respectively. Overall median survival was 2.6 months. Patients with malignant pericardial effusion, especially those with primary lung cancer have poor survival rates. In advanced malignancy, the subxiphoid pericardial window procedure provides only short-term palliation of symptoms, and has no effect on long-term survival. The use of any surgical procedure in patients with malignant advanced pericardial effusion should be considered along with nonsurgical options on a case-by-case basis depending on symptoms, general status, and expected survival.
引用
收藏
页码:72 / 73
页数:2
相关论文
共 15 条
[1]   Subxiphoid pericardiostomy in the management of pericardial effusions:: case series analysis of 368 patients [J].
Becit, N ;
Ünlü, Y ;
Ceviz, M ;
Koçogullari, CI ;
Koçak, H ;
Gürlertop, Y .
HEART, 2005, 91 (06) :785-790
[2]   Large symptomatic pericardial effusion as the presentation of unrecognized cancer - A study in 173 consecutive patients undergoing pericardiocentesis [J].
Ben-Horin, S ;
Bank, I ;
Guetta, V ;
Livneh, A .
MEDICINE, 2006, 85 (01) :49-53
[3]   ETIOLOGY OF LARGE PERICARDIAL-EFFUSIONS [J].
COREY, GR ;
CAMPBELL, PT ;
VANTRIGT, P ;
KENNEY, RT ;
OCONNOR, CM ;
SHEIKH, KH ;
KISSLO, JA ;
WALL, TC .
AMERICAN JOURNAL OF MEDICINE, 1993, 95 (02) :209-213
[4]   Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy [J].
Cullinane, CA ;
Paz, IB ;
Smith, D ;
Carter, N ;
Grannis, FW .
CHEST, 2004, 125 (04) :1328-1334
[5]   Pericardial effusion in patients with cancer: Outcome with contemporary management strategies [J].
Laham, RJ ;
Cohen, DJ ;
Kuntz, RE ;
Baim, DS ;
Lorell, BH ;
Simons, M .
HEART, 1996, 75 (01) :67-71
[6]   Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade [J].
Liu, G ;
Crump, M ;
Goss, PE ;
Dancey, J ;
Shepherd, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) :3141-3147
[7]   Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade [J].
Maher, EA ;
Shepherd, FA ;
Todd, TJR .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 112 (03) :637-643
[8]   Percutaneous treatment in patients presenting with malignant cardiac tamponade [J].
Marcy, PY ;
Bondiau, PY ;
Brunner, P .
EUROPEAN RADIOLOGY, 2005, 15 (09) :2000-2009
[9]   Intrapericardial treatment of neoplastic pericardial effusions [J].
Martinoni, A ;
Cipolla, CM ;
Civelli, M ;
Cardinale, D ;
Lamantia, G ;
Colleoni, M ;
DeBraud, F ;
Susini, G ;
Martinelli, G ;
Goldhirsh, A ;
Fiorentini, C .
HERZ, 2000, 25 (08) :787-793
[10]  
OKAMOTO H, 1993, CANCER-AM CANCER SOC, V71, P93, DOI 10.1002/1097-0142(19930101)71:1<93::AID-CNCR2820710115>3.0.CO